This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Currently there are no upcoming events.
Discover the microscopic organisms that inhabit our bodies and new microbiome-based treatment strategies in the clinic.
Discover how doctors and patients can recognize and safely manage an overstimulated or misdirected immune response with Dr. Jeffrey S. Weber of NYU Langone Health.
Discover the full potential of genome-based medicine with genomic and genetic testing for cancer risk and tumor assessment with Corrie Painter, Ph.D., and Eliezer Van Allen, M.D.
Discover antibody-based imaging strategies that help doctors visualize patients’ tumors and immune cells in real-time via PET scans.
Dr. Padmanee Sharma of MD Anderson discusses what breakthroughs and advances might lie ahead for the field of cancer immunotherapy in 2020.
Dr. Michel Sadelain of Memorial Sloan Kettering highlights a revolutionary new treatment approach—CAR T cell immunotherapy—that he helped pioneer.
Brendan Connors and his oncologist Dr. Michael Postow of Memorial Sloan Kettering discuss the importance of communication between patient and doctor throughout immunotherapy treatment.
Dr. Patrick Hwu of the MD Anderson highlights the promise and potential of combination immunotherapies and how biomarkers can be used to guide these strategies.
Dr. Elizabeth M. Jaffee of Johns Hopkins University discusses cancer immunotherapy’s ongoing efforts to overcome the challenges ahead and enable immunotherapy to benefit even more people with cancer.
Caregivers Casey Zmudzinski and Benny Juarez, and cancer veteran Kristin Kleinhofer, discuss how they advocate for the best care possible for their loved ones.
CRI.ContactUs
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
In February 2017, Oswald became one of the first patients to receive pembrolizumab (Keytruda®) as first-line therapy for non-small cell lung cancer.
Dr. Kunle Odunsi discusses genomic testing, new treatments, and promising clinical trials in immunotherapy for ovarian cancer.